Remove Heart Valves Remove Stroke Remove TAVR
article thumbnail

Redo-TAVR with balloon-expandable valves: outcomes from a national registry

Cardiology Update

In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0%

TAVR 52
article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients TAVR Expected to See Rapid Growth in Next 5 years FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients Portico TAVR System Reduces Severe (..)

Tricuspid 102
article thumbnail

Groundbreaking Data in Interventional Cardiology to be Featured at Society for Cardiovascular Angiology and Interventions SCAI 2024 Scientific Sessions

DAIC

According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States. PAD contributes to 400 amputations each day.

article thumbnail

Self-Expanding Valve Outperforms Balloon-Expandable Valve for TAVR in Patients with Small Valve Annulus

DAIC

The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. percentage points—in one-year bioprosthetic valve dysfunction favoring the Evolut platform. of those receiving the SAPIEN valve.

TAVR 59
article thumbnail

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

DAIC

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. At Medtronic, we continue to emphasize that valve design matters. healthcare system perspective.

TAVR 52
article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Part 1: Concepts, Indicator Variables, and Controversies The Annals of Thoracic Surgery January 2022 Arman Kilic Supplementing Existing Societal Risk Models for Surgical Aortic Valve Replacement With Machine Learning for Improved Prediction Journal of the American Heart Association November 2021 Jared Belle Strategies for Mechanical Right Ventricular (..)

article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)